Dr. Jasmin Barman-Aksözen's personal experience with erythropoietic protoporphyria (EPP) led her to contribute to the development and approval of Scenesse, the first treatment for this rare genetic disorder.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.